Nicholas Hutchings will discuss how recombinant antibody technology can speed up the response to a pandemic.

Identifying molecular targets for SARS-CoV-2 therapeutics.

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

Clinical trials were halted after the treatment’s vector that ferries in the healthy genetic sequence was identified in the genome of a patient’s cancer cells.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

A study has sparked controversy by suggesting that cells made using a popular lab protocol have been misidentified, with potentially serious repercussions for brain research. Critics say the significance of the findings has been overstated.

The review of more than two dozen studies finds aripiprazole has side effects and does not change core autism features, but parents report improvements in self-injury, tantrums, and other challenging behaviors.

Facing new variants of SARS-CoV-2, some vaccines may offer more robust protection or be more easily redesigned to target them.

Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.